Skip to main content

Remote Job Finders (RJF)

Vertex carries M&A uptick into H2, IPOs and VC raises also grow, FDA on pace despite turmoil

A surprising deal from Vertex Pharmaceuticals adds to Big Pharma’s acquisitive streak as Crinetics folds into the cystic fibrosis drugmaker. Meanwhile, IPOs and venture capital raises trend upward, but mostly for derisked companies. Plus, FDA decisions slow only slightly as the hunt for a permanent leader drags on.

Hair loss biotech Veradermics, up 656% since its IPO, credits the obesity boom

After debuting on the public markets with $256.3 million and raking in an additional $472 million, Veradermics has emerged as one of biotech’s biggest post-IPO standouts. CEO Reid Waldman credits the weight loss craze for establishing consumer-driven channels.

Genentech culls 103 jobs, inks $490M-plus biobucks deal with Astex

With the latest round, Roche’s Genentech will have racked up nearly 450 layoffs in California over the last year amid ongoing restructuring. At the same time, the biotech is joining forces with Astex Pharmaceuticals in a deal that could surpass $490 million.
Scroll to top